Market revenue in 2023 | USD 7.5 million |
Market revenue in 2030 | USD 13.0 million |
Growth rate | 8.1% (CAGR from 2023 to 2030) |
Largest segment | Human donor tissue-derived products |
Fastest growing segment | Human Donor Tissue-Derived Products |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Human Donor Tissue-Derived Products, Acellular Animal-derived Products |
Key market players worldwide | 3M Co, Organogenesis Holdings Inc Class A, Integra Lifesciences Holdings Corp, Smith & Nephew PLC, MiMedx Group Inc, Essity AB Class B, Stryker Corp, Vericel Corp, Mallinckrodt PLC Ordinary Shares - New, Tissue Regenix |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to biological skin substitutes market will help companies and investors design strategic landscapes.
Human donor tissue-derived products was the largest segment with a revenue share of 66.67% in 2023. Horizon Databook has segmented the Italy biological skin substitutes market based on human donor tissue-derived products, acellular animal-derived products covering the revenue growth of each sub-segment from 2018 to 2030.
According to Italy Country Profile 2021, heart diseases, stroke, lung cancer, COPD, and diabetes followed by COVID-19 were among the major causes of death in the country in 2020. The Italy Country Profile also reports that life expectancy in Italy was higher as compared to other European countries.
The high burden of chronic diseases and high life expectancy are expected to improve the demand for technologically advanced medical devices for diagnosis and treatment in the country. This is expected to create opportunities for medical device outsourcing services in the country.
A large number of key players in the medical device CDMOs are present in Italy, including Medpace, Charles River, Labcorp, Icon, IQVIA, Parexel, and PRA Health Science. The growing demand for reducing costs of clinical research, manufacturing, and development among medical device companies is expected to increase the number of partnerships with CDMOs in the coming years, thus boosting the Italy medical device outsourcing market.
Horizon Databook provides a detailed overview of country-level data and insights on the Italy biological skin substitutes market , including forecasts for subscribers. This country databook contains high-level insights into Italy biological skin substitutes market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account